retatrutide and joint pain UK 2026: Phase 3 Results Rheumatoid Arthritis - UF Health

Upon subgroup analysis, they observed a lower risk of mortality associated with the use of GLP-1 receptor agonists compared with DDP-4 inhibitors among patients with cerebrovascular disease (HR, 0.33) than among those without the cerebrovascular disease (HR, 0.89)

Seaweed or kelp supplements should be avoided due to variable and potentially excessive iodine content

One problem that some people worry about is a bowel obstruction

It can also be prescribed for its potential to promote weight loss as an off-label use

Best fit for: Those wanting the maximum possible weight loss Patients needing treatment outside China Individuals requiring extensive safety and cardiovascular outcome data People with type 2 diabetes or heart failure with preserved ejection fraction Anyone seeking a globally approved medication Who Should Consider Mazdutide

Here is what has occurred and what patients may expect in the coming months based on manufacturer announcements and regulatory filings: December 22, 2025: FDA approved oral Wegovy (semaglutide 25 mg), the first oral GLP-1 for weight loss